The RNA inhibitor olpasiran significantly reduces a type of "bad cholesterol" that's associated with a high risk of cardiovascular events, according to results from an analysis by a Mount Sinai ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Research reveals semaglutide's effectiveness in decreasing alcohol consumption and cravings, highlighting its potential for treating alcohol use disorder.

New dyslipidemia guidance from the American Association of Clinical Endocrinology focuses on newer medications and patient-important outcomes.

The FDA has accepted for review the BLA for lerodalcibep to reduce LDL-C in patients with or high risk of ASCVD and primary hyperlipidemia.

Welcome to the UK's Official Charts! In addition to the Official Singles and Albums Chart, did you know the Official Charts Company compiles 50+ charts every week, spanning different genres and ...